(Q35586753)

9 August 2017

1 reference

title

From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? (English)

1 reference

9 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

3 April 2024

author name string

P. D. Skosnik

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623490

3 April 2024

J. K. Yao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623490

3 April 2024

language of work or name

1 reference

1 December 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S0952327803001601?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

https://api.elsevier.com/content/article/PII:S0952327803001601?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Prostaglandins, Leukotrienes and Essential Fatty Acids

3 April 2024

published in

1 reference

9 August 2017

volume

69

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

367-384

1 reference

Psychopathologic Precursors and Sociodemographic Risk Factors for the Schizophrenia Syndrome

9 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Psychopharmacologic treatment of schizophrenia

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

3 April 2024

Schizophrenia

7

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Neurochemistry and neuroendocrinology of schizophrenia: a selective review

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Schizophrenia as a membrane lipid disorder which is expressed throughout the body

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Schizophrenia as a prostaglandin deficiency disease

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Possible association of schizophrenia with a disturbance in prostaglandin metabolism: a physiological hypothesis

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Implications of lipid biology for the pathogenesis of schizophrenia

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Schizophrenia: The role of abnormal essential fatty acid and prostaglandin metabolism

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Erythrocyte membrane phospholipids in psychotic patients

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology.

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Antipsychotics and phospholipid metabolism in schizophrenia

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia.

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The evolution of desaturases

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Recent advances in the study of fatty acid desaturases from animals and lower eukaryotes

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential fatty acids in plasma phospholipids in schizophrenics

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Arachidonic Acid: A Common Link in the Biology of Schizophrenia?

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

3 April 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Fatty acids and schizophrenia

3 April 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

3 April 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects.

3 April 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia

3 April 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline

3 April 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: a study of normal subjects from Italy, Finland, and the USA.

3 April 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Long‐term storage of red blood cells and correlations between red cell and dietary fatty acids: Results from a pilot study

3 April 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Fat consumption and schizophrenia.

3 April 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The relationship between schizophrenia and essential fatty acid and eicosanoid metabolism

3 April 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Prevalence of smoking among psychiatric outpatients

3 April 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers.

3 April 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The effects of cigarette smoking on the metabolism of essential fatty acids

3 April 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Free-radical chemistry of cigarette smoke and its toxicological implications

3 April 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The role of free radicals and antioxidants

3 April 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Influence of nicotine and cotinine on retinal phospholipase A2 and its significance to macular function

3 April 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Nicotine-induced inhibition of neuronal phospholipase A2

3 April 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Phospholipase A2 in Schizophrenia

3 April 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Elevated PLA2 activity in schizophrenics and other psychiatric patients

3 April 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

3 April 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder

3 April 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Environmental factors and membrane polyunsaturated fatty acids in schizophrenia

3 April 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics

3 April 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Membrane fatty acids, niacin flushing and clinical parameters

3 April 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment

3 April 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group

3 April 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Fatty acid levels in the brains of schizophrenics and normal controls.

3 April 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

3 April 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia.

3 April 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia.

3 April 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy.

3 April 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms.

3 April 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study

3 April 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls.

3 April 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders.

3 April 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

In vivo incorporation from plasma of radiolabeled palmitate and arachidonate into rat brain microvessels.

3 April 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Brain incorporation of [1-11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography.

3 April 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography

3 April 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Diseases of phospholipid metabolism as possible pathogenetic factors in schizophrenia. Current findings and critical evaluation

3 April 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes.

3 April 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites

3 April 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy

3 April 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased platelet phospholipase A2 activity in schizophrenia.

3 April 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients

3 April 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The expanding superfamily of phospholipase A(2) enzymes: classification and characterization

3 April 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased phospholipase A2 activity in schizophrenia with absent response to niacin

3 April 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Genetic variant near cytosolic phospholipase A2 associated with schizophrenia

3 April 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia

3 April 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Is the cPLA2 gene associated with schizophrenia?

3 April 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene

3 April 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia.

3 April 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Lack of association between schizophrenia and the phospholipase-A(2) genes cPLA2 and sPLA2.

3 April 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples

3 April 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased concentrations of phosphatidylinositol (PI) and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses

3 April 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Reduced plasma antioxidants in first-episode patients with schizophrenia

3 April 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Reduced status of plasma total antioxidant capacity in schizophrenia.

3 April 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Reduced level of plasma antioxidant uric acid in schizophrenia.

3 April 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

3 April 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment

3 April 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Elevated plasma lipid peroxides at the onset of nonaffective psychosis

3 April 2024

112

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance

3 April 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines

3 April 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia

3 April 2024

115

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Schizophrenia; a new approach. II. Result of a year's research

3 April 2024

117

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Arachidonic acid as a neurotoxic and neurotrophic substance

3 April 2024

118

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Metabolites of arachidonic acid in the nervous system of Aplysia: possible mediators of synaptic modulation

3 April 2024

119

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Calcium-independent activation of hypothalamic type I protein kinase C by unsaturated fatty acids

3 April 2024

120

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Arachidonic acid induces a long-term activity-dependent enhancement of synaptic transmission in the hippocampus

3 April 2024

121

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential fatty acids modulate apomorphine activity at dopamine receptors in cat caudate slices

3 April 2024

122

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia

3 April 2024

124

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Schizophrenia: a subcortical neurotransmitter imbalance syndrome?

3 April 2024

125

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis

3 April 2024

126

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells

3 April 2024

127

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Rapid regulation of neurite outgrowth and retraction by phospholipase A2-derived arachidonic acid and its metabolites

3 April 2024

129

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

GAP-43: an intrinsic determinant of neuronal development and plasticity

3 April 2024

131

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Neurite outgrowth stimulated by neural cell adhesion molecules requires growth-associated protein-43 (GAP-43) function and is associated with GAP-43 phosphorylation in growth cones.

3 April 2024

132

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Activation of protein kinase C by arachidonic acid selectively enhances the phosphorylation of GAP-43 in nerve terminal membranes

3 April 2024

133

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Arachidonic acid, but not sodium nitroprusside, stimulates presynaptic protein kinase C and phosphorylation of GAP-43 in rat hippocampal slices and synaptosomes

3 April 2024

134

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Antisense GAP-43 inhibits the evoked release of dopamine from PC12 cells

3 April 2024

135

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased levels of GAP-43 protein in schizophrenic brain tissues demonstrated by a novel immunodetection method

3 April 2024

136

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia

3 April 2024

137

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia

3 April 2024

138

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Clinical and laboratory evidence of autoimmunity in acute schizophrenia

3 April 2024

140

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Polyunsaturated fatty acids, inflammation, and immunity.

3 April 2024

141

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Schizophrenia and Rheumatoid Arthritis

3 April 2024

142

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Negative association between schizophrenia and rheumatoid arthritis

3 April 2024

143

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

At issue: schizophrenia and rheumatoid arthritis: the negative association revisited

3 April 2024

144

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both?

3 April 2024

145

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production

3 April 2024

146

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins

3 April 2024

147

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

3 April 2024

148

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Elevated interleukin-6 in schizophrenia

3 April 2024

149

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness

3 April 2024

150

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

3 April 2024

151

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology.

3 April 2024

152

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Molecular mechanisms of platelet activation

3 April 2024

153

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Inositol phospholipid turnover in platelets of schizophrenic patients

3 April 2024

154

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The platelet polyphosphoinositide system in schizophrenia: the effects of neuroleptic treatment

3 April 2024

155

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased turnover of platelet phosphatidylinositol in schizophrenia

3 April 2024

156

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Raised monophosphatase activity in schizophrenic patients

3 April 2024

157

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Lack of effect of inositol treatment in chronic schizophrenia.

3 April 2024

158

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Agonist-induced, GTP-dependent phosphoinositide hydrolysis in postmortem human brain membranes.

3 April 2024

159

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Assay of a phosphatidylinositol bisphosphate phospholipase C activity in postmortem human brain

3 April 2024

160

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Phosphoinositide signaling in human brain

3 April 2024

161

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Transmembrane signaling through phospholipase C in human cortical membranes.

3 April 2024

162

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence.

3 April 2024

163

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain

3 April 2024

164

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

3 April 2024

165

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Determination and characterization of a cannabinoid receptor in rat brain

3 April 2024

166

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Neurobiology of marijuana abuse.

3 April 2024

167

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

3 April 2024

168

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Cannabinoid/anandamide system and schizophrenia: is there evidence for association?

3 April 2024

169

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Elevated endogenous cannabinoids in schizophrenia

3 April 2024

170

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Cannabis use is associated with schizotypy and attentional disinhibition.

3 April 2024

171

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal

3 April 2024

172

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Are cannabinoid receptor knockout mice animal models for schizophrenia?

3 April 2024

173

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

3 April 2024

174

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance

3 April 2024

175

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Arachidonic acid release and prostaglandin F(2alpha) formation induced by anandamide and capsaicin in PC12 cells

3 April 2024

176

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

3 April 2024

178

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1

3 April 2024

179

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia

3 April 2024

180

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients

3 April 2024

181

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines

3 April 2024

182

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

3 April 2024

183

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Dyskinesias and their treatment with essential fatty acids: a review

3 April 2024

184

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933

3 April 2024

185

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

3 April 2024

186

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Niacin test in schizophrenia and affective illness

3 April 2024

188

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Niacin skin flush in schizophrenia: a preliminary report

3 April 2024

191

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia

3 April 2024

193

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Relationship between the niacin skin flush response and essential fatty acids in schizophrenia

3 April 2024

195

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Dyslexia, handedness and syndromes of psychosis-proneness

3 April 2024

196

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Language and schizophrenia

3 April 2024

197

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Language comprehension in schizophrenics and their brothers

3 April 2024

199

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The language system in schizophrenia: effects of capacity and linguistic structure.

3 April 2024

200

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Long-term adverse effects of scuba diving

3 April 2024

201

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Increased levels of cytosolic phospholipase A2 in dyslexics

3 April 2024

203

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A lack of essential fatty acids as a possible cause of hyperactivity in children

3 April 2024

204

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder

3 April 2024

205

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A comparison of the personality profile (16 P.F.) of eminent researchers with that of eminent teachers and administrators, and of the general population

3 April 2024

207

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A Comparative Study of Attentional Strategies of Schizophrenic and Highly Creative Normal Subjects

3 April 2024

208

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Psychoticism and thinking

3 April 2024

209

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Psychoses and creativity: is the missing link a biological mechanism related to phospholipids turnover?

3 April 2024

211

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Undergraduate marijuana use as related to internal sensation novelty seeking and openness to experience

3 April 2024

212

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent

3 April 2024

213

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Essential fatty acid supplementation in tardive dyskinesia

3 April 2024

216

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid

3 April 2024

217

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding

3 April 2024

218

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

The potential role of fatty acids in attention-deficit/hyperactivity disorder.

3 April 2024

219

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia

3 April 2024

220

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

3 April 2024

221

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Clozapine for Treatment-Refractory Schizophrenia, Schizoaffective Disorder, and Psychotic Bipolar Disorder

3 April 2024

222

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Arachidonic acid binds to apolipoprotein D: implications for the protein's function

3 April 2024

224

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy

3 April 2024

226

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders

3 April 2024

227

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome

3 April 2024

229

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Systemic lithium administration alters rat cerebral cortex phospholipids

3 April 2024

230

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Lithium decreases turnover of arachidonate in several brain phospholipids.

3 April 2024

231

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers

3 April 2024

232

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

3 April 2024

233

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

Control of pain initiation by endogenous cannabinoids.

3 April 2024

234

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.008

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference